Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06953583 · ClinicalTrials.gov registry record · Phase 3
A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)
A Phase 3 study of Friedreich Ataxia, sponsored by Biogen.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 255
- Enrollment target
- 20
- Study locations
NCT06953583 is a Phase 3 study of Friedreich Ataxia that is actively recruiting participants, run by Biogen. The registered enrollment target is 255 participants, below the 431-participant average among 14 other Friedreich Ataxia trials with a reported enrollment target (41% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06953583, a Phase 3 study of Friedreich Ataxia, is actively recruiting participants, sponsored by Biogen.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 255 participants
- Enrollment target
- 20
- Study locations
Study Summary
In this study, researchers will learn more about the effects and safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedreich's Ataxia (FA) who are at least 16 years old. But, it is not yet available for children and teens with FA who are younger than 16 years old. The main objective of this study is to learn how BIIB141 works in the body and about its safety in children and teens who are 2 to 15 years old. The main questions researchers want to answer in this study are: * How does BIIB141 affect the participants' FA symptoms balance and stability? * How many participants have medical problems during the study? * Are there any changes in the participants' overall health during the study? * Are there any changes in the participants' heart health? * Are there any changes in how the participants move through puberty? Puberty is the time in someone's life when their body changes from a child to an adult. Researchers will also learn more about: \- How the body processes BIIB141 in children and teens This study will be done as follows: * Participants will be screened to check if they can join the study. The screening period will be up to 28 days, after which participants will check into their study research center. * There are 2 parts in this study. During Part 1, participants will take either BIIB141 or a placebo once a day. * In Part 1, participants will take BIIB141 or the placebo in a study research center on Day 1, and then at in-person visits at Week 4, Week 12, Week 26, and Week 52. On all other days, they will take BIIB141 or the placebo at home. Part 1 lasts up to 52 weeks. * During Part 2, participants from Part 1 will either continue taking BIIB141 or start it if they were taking the placebo. Part 2 will last up to 104 weeks. * In Part 1, participants will have up to 10 visits to their study research center and a phone call at Week 2. In Part 2, participan
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Omaveloxolone
Study Locations (20)
Other
- Universitätsklinikum Innsbruck - Innsbruck
- Rigshospitalet - Juliane Marie Centret (JMC) Copenhagen - Copenhagen
- AP-HP - Hôpital Armand Trousseau - Paris
- UKGM - Universitätsklinikum Giessen und Marburg GmbH - Standort Gießen - Giessen
Florida
- Norman Fixel Institute for Neurological Diseases UF Health - Gainesville
- USF Health Morsani College of Medicine Department of Neurology - Tampa
São Paulo
- University of Campinas (UNICAMP) School of Medical Sciences - Campinas
- PSEG Centro de Pesquisa Clinica - São Paulo
Quebec
- McGill University - Montreal
- CHU de Quebec -Universite Laval - Québec
California
- UCLA Neurology Outpatient Clinic at Westwood - Los Angeles
Pennsylvania
- Children's Hospital of Philadelphia - Buerger Center for Advanced Pediatric Care - PIN - Philadelphia
Tennessee
- St. Jude Children's Research Hospital - PIN - Memphis
Virginia
- CHKD's Health Center - South Campus - PIN - Norfolk
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 255 participants |
| Start Date | 2025-06-09 |
| Est. Completion | 2029-11-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06953583
The ClinicalTrials.gov registry entry for NCT06953583 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 255 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 431-participant average among 14 other Friedreich Ataxia trials with a reported enrollment target (41% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Friedreich Ataxia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06953583 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Florida, São Paulo.
Frequently Asked Questions
What is clinical trial NCT06953583 about?
NCT06953583 is a clinical study titled "A Study to Learn More About the Effects and Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old (BRAVE)". In this study, researchers will learn more about the effects and safety of BIIB141, also known as omaveloxolone or SKYCLARYS®. This drug has been approved, or made available for doctors to prescribe, for people with Friedreich's Ataxia (FA) who are at least 16 years old. But, it is not yet available...
What is the current status of trial NCT06953583?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 255 participants. The study started on 2025-06-09. Estimated completion is 2029-11-22.
What conditions does trial NCT06953583 study?
This clinical trial studies the following conditions: Friedreich Ataxia.
What interventions are being tested in trial NCT06953583?
The interventions under investigation include: Placebo (DRUG), Omaveloxolone (DRUG).
Who is sponsoring clinical trial NCT06953583?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06953583 being conducted?
This trial has 20 study locations across California, Florida, Pennsylvania, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Friedreich Ataxia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Assess the Safety and Efficacy of Vatiquinone in Participants With Friedreich Ataxia
ACTIVE NOT RECRUITING · Phase 3
-
Clinical Course Of Disease In Participants With FA-CM
RECRUITING
-
A Study to Learn More About the Long-Term Safety of BIIB141 (Omaveloxolone) in Participants With Friedreich's Ataxia Who Are Prescribed it by Their Own Doctors
RECRUITING
-
A Study to Find Out How BIIB141 (Omaveloxolone) is Processed in the Body and to Learn More About Its Safety in Participants With Friedreich's Ataxia Aged 2 to 15 Years Old
RECRUITING · Phase 1
-
Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia
RECRUITING · Phase 1
-
A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.